|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
CFH and ARMS2 risk alleles do not modify the response to the AREDS2 nutrient supplements with respect to the progression to late AMD (GA and neovascular AMD).
|
31358387 |
2019 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Patients with GA were significantly older, with a higher prevalence of reticular pseudodrusen, bilateral involvement of advanced AMD and T-allele frequency of ARMS2 A69S compared with those with typical AMD and PCV; although there were no differences in the genetic and clinical characteristics among patients with GA and RAP.
|
26918864 |
2016 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.
|
26691988 |
2016 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The ARMS2 variant rs10490924 was significantly more frequent in dt-GA than in 1000G individuals (Pcorrected < 0.01).
|
27149696 |
2016 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Odds ratios, especially for the main risk polymorphisms in ARMS2 (rs10490924) and CFH (rs1061170), gained with increasing disease severity and bilateralism (exemplarily: rs1061170: unilateral early AMD: OR = 1.18; bilateral early AMD: OR = 1.20; unilateral intermediate AMD: OR = 1.28; bilateral intermediate AMD: OR = 1.39, unilateral geographic atrophy (GA): OR = 1.50; bilateral GA: OR = 1.71).
|
27257685 |
2016 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Analyzing the currently largest dataset on GA lesion growth (N = 388), our findings suggest a significant and independent contribution of three factors on GA lesion growth including at least two genetic factors (ARMS2_rs10490924 [P < 0.00088] and C3_rs2230199 [P < 0.00015]) as well as one clinical component (presence of GA in the fellow eye [P < 0.00023]).
|
25962167 |
2015 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Early AMD lesion characteristics were assessed for association with GA incidence using eye-specific data and generalized estimating equation models adjusting for age, current smoking, and presence of risk alleles of the complement factor H (CFH) or age-related maculopathy susceptibility 2 (ARMS2) genes, genotyped or imputed using genome-wide scan data.
|
23706948 |
2013 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
DHA was not associated with reduced risk of GA among those with the homozygous ARMS2/HTRA1 nonrisk genotype (HR, 1.0; P = 0.90).
|
23481534 |
2013 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Smoking status and ARMS2 genotype had less of an impact on the prediction of GA compared with CNV.
|
23523162 |
2013 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Although genetic markers were associated significantly with 3-year CNV (CFH: Y402H; ARMS2: A69S) and GA incidence (CFH: Y402H), the inclusion of genetic factors in the models provided only marginal improvements in predictive performance.
|
22704140 |
2012 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In this series, in patients with geographic atrophy or choroidal neovascularization in at least 1 eye, the ARMS2 A69S substitution strongly associated with geographic atrophy or choroidal neovascularization in the fellow eye.
|
22481475 |
2012 |
|
Geographic Atrophy
|
0.200 |
Biomarker
|
disease |
BEFREE |
The genes CFH, C3, CFB, and ARMS2/HTRA1 were associated with progression from intermediate drusen to large drusen and from large drusen to GA or NV.
|
22247473 |
2012 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes.
|
22705344 |
2012 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The frequency of the T allele of ARMS2/HTRA1 rs10490924 was significantly higher in participants with CNV than in those with geographic atrophy (OR, 1.37; 95% confidence interval, 1.21-1.54; P value = 4.2 × 10(-7)).
|
21122828 |
2011 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
For the single nucleotide polymorphism rs10490924 in LOC387715/ARMS2, there was a significant association of GA growth rate, both adjusted and unadjusted for initial lesion size, with the homozygous risk genotype as compared with the homozygous nonrisk genotype (unadjusted P = 0.002; Bonferroni-corrected P = 0.014) and for allelic association (Bonferroni-corrected P value = 0.011).
|
20381870 |
2010 |
|
Geographic Atrophy
|
0.200 |
Biomarker
|
disease |
BEFREE |
This study confirms that variants at CFH, C3, and ARMS2 confer significant risks for GA due to AMD.
|
19823576 |
2009 |
|
Geographic Atrophy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We genotyped three SNPs, rs1061170 (exon 9, CFH), rs11200638 (HTRA1 promoter, -512 bp), and rs10490924 (6.6 kb upstream of HTRA1 in LOC387715/ARMS2) in 333 cases with advanced AMD (choroidal neovascularization [CNV] and geographic atrophy) and 171 age-matched examined controls.
|
18682806 |
2008 |